1. Elucidation of molecular pathogenesis and drug development for psychiatric disorders from rare disease-susceptibility variants
- Author
-
Norio Ozaki, Daisuke Mori, Branko Aleksic, and Hiroki Kimura
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Disease ,Biology ,Polymorphism, Single Nucleotide ,Genome ,Mice ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,Drug Development ,medicine ,Animals ,Genetic Predisposition to Disease ,Psychiatry ,Induced pluripotent stem cell ,Allele frequency ,Psychiatric genetics ,Comparative Genomic Hybridization ,Mental Disorders ,General Neuroscience ,General Medicine ,030104 developmental biology ,Drug development ,030217 neurology & neurosurgery ,Comparative genomic hybridization ,Rare disease - Abstract
Recent rapid progress in genome analysis and large-scale consortia has made it possible to discover variants with a variety of allele frequencies and effect sizes associated with psychiatric disorders. Among psychiatric disorder-susceptibility variants, rare variants with large effect sizes detected by sequencing analysis or array comparative genomic hybridization would be particularly useful for elucidating pathophysiology by developing disease models, such as genome-edited mouse or induced pluripotent stem cells. In the last decade, investigations of rare variants with large effect size have revealed an important role of neurodevelopment in the pathogenesis of psychiatric disorders. In future research, integration of recent evidence concerning the contribution of the immune system or gut microbiota will enhance our understanding of psychiatric disorders and facilitate novel drug development.
- Published
- 2021